NCT06072820Withdrawn
Analytical Evaluation of the Endotest® Diagnostic
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Reason given: Study split into two independants studies
Brief summary (registry, in English)
This is an interventional with minimal risks and constraints (RIPH 2 in France), prospective, longitudinal, non-randomized, multicenter study. The present study will allow us to evaluate multiple factors assessing the Endotest® Diagnostic accuracy and its possible limitations. To characterize the Endotest® Diagnostic, the following parameters will be evaluated: * Repeatability: the verification of the invariability of its results without condition changes, * Circadian cycle: whether the circadian cycle affects the determination of the signature, * Intermediate fidelity: the verification of the invariability of its results with an operator change, * Interferences: the impact of different interferences on its results, * Stability: the possible modification of its results depending on the samples conditions of storage. The acts and procedures performed in this research will be divided into three visits: * Inclusion visit: performance of 4 Endotest® Diagnostics (3 at the visit and 1 at home) by the 60 included subjects, * "Circadian cycle" visit: performance of 17 Endotest® Diagnostics (14 at the visit and 3 post-visit at home) by 6 subjects selected after evaluation of the results of the inclusion visit, * "Repeatability-intermediate fidelity-interference-stability" visit: realization of 17 Endotest® Diagnostic by 10 or 16 subjects, depending on the results of the impact of the circadian cycle on the saliva signature. These subjects will be selected according to the results of the inclusion visit, excluding those who participated in the circadian cycle visit.
- Status (registry)
- Withdrawn
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 2 Oct 2023
- Start date
- Oct 2023
- Primary completion date
- Jan 2024
- Lead sponsor
- ZIWIG
- Diseases
- Endometriosis
- NCT number
- NCT06072820
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subject with acute or chronic infection (viral hepatitis, HIV...),
Other
- Pregnant subject,
- Subject unable to comply with study and/or follow-up procedures (including absence of outside salivary sample after the inclusion visit),
- Subject participating in an interventional study or in the exclusion period of an interventional study.
Who the study is looking for
- Subject aged 18 years to 43 years,
- Subject having dated and signed the consent form,
- Subject affiliated to the French health system,
- Subject able to return for a full day for the rest of the study,
- Subject whose diagnosis of endometriosis has been established with certainty or definitively ruled out.
- Non-Inclusion criteria:
- Pregnant subject,
- Subject with an acute or chronic infection (viral hepatitis, HIV...),
- Subject with history of hypersensitivity or allergy,
- Subject with a personal history of cancer,
- Subjects with significant difficulties in reading or writing the French language,
- Subject unable to comply with the study and/or follow-up procedures,
- Subject who has objected to the collection of her data,
- Subject participating in an interventional study or in the exclusion period of an interventional study.
Age in the registry: 18 years to 43 years · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinique Tivoli | Bordeaux | France | Unknown status |
| CHU de Rouen | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.